Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 7,073 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mammary Cancer Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane

NCT03930680
View directory record Official record
Conditions
Degradation of Top2b and Top2a in Human by Dexrazoxane, Time Course and Degradation of Top2b in Human by Dexrazoxane, Effects of Dexrazoxane on Healthy Human
Interventions
Dexrazoxane
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 26, 2026, 5:36 PM EDT
Recruiting Not applicable Interventional

The MIND-BC Study: MIND Diet for Breast Cancer Cognition

NCT07018986
View directory record Official record
Conditions
Breast Cancer
Interventions
MIND Diet, Usual Diet
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 26, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

NCT00028405
View directory record Official record
Conditions
Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma, Rectal Cancer, Breast Cancer, Colorectal Cancer, Mouth Cancer
Interventions
LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
Drug · Device
Lead sponsor
Light Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
6
States / cities
Tucson, Arizona • Detroit, Michigan • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Dissemination of BREASTChoice AIM1-B

NCT07396766
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Baseline Questionnaire, Semi structured Interview, Post Survey
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 26, 2026, 5:36 PM EDT
Not listed No phase listed Observational

TME Neoadjuvant Breast Registry

NCT02596724
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Genomic and/or molecular testing of blood or tissue
Other
Lead sponsor
Targeted Medical Education
Other
Eligibility
18 Years to 90 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Los Gatos, California • Allentown, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 26, 2026, 5:36 PM EDT
Not listed Phase 1 Interventional

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

NCT04460456
View directory record Official record
Conditions
HER2 Positive Solid Tumors
Interventions
SBT6050, pembrolizumab, Cemiplimab
Drug
Lead sponsor
Silverback Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 26, 2026, 5:36 PM EDT
Active, not recruiting Phase 1 Interventional

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 26, 2026, 5:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

HydroMARK Post-market Clinical Follow-up Study

NCT04622696
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrasound imaging
Diagnostic Test
Lead sponsor
Devicor Medical Products, Inc.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Columbus, Ohio • Toledo, Ohio • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 26, 2026, 5:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

NCT02615054
View directory record Official record
Conditions
Trastuzumab Cardiotoxicity, HER2-Positive Breast Cancer Survivors
Interventions
2D Echocardiogram, Cardiopulmonary exercise testing and post-CPET cardiac function
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 26, 2026, 5:36 PM EDT
Active, not recruiting No phase listed Observational

Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer

NCT07092254
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
No drug
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 5:36 PM EDT
Terminated No phase listed Observational

Role of Beta-Endorphin in Cancer Therapy Fatigue

NCT01113905
View directory record Official record
Conditions
Breast Cancer, Fatigue
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 26, 2026, 5:36 PM EDT
Recruiting Phase 1 Interventional

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029
View directory record Official record
Conditions
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Interventions
ONM-501, Cemiplimab
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 26, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available

Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer

NCT03360695
View directory record Official record
Conditions
Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer
Interventions
Proactive Psychiatry Consultation (PPC), Enhanced Usual Care (EUC)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 26, 2026, 5:36 PM EDT
Completed No phase listed Observational

Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer

NCT01282931
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Not listed
Lead sponsor
Health Outcomes Solutions
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 26, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Results available

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937
View directory record Official record
Conditions
Advanced Cancer
Interventions
LY3475070, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 26, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Prayer as a Possible Adjuvant Treatment for Breast Cancer

NCT00519545
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Prayer
Behavioral
Lead sponsor
Southwestern Regional Medical Center
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 26, 2026, 5:36 PM EDT
Active, not recruiting No phase listed Observational

IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

NCT03536897
View directory record Official record
Conditions
Breast Cancer
Interventions
IORT
Radiation
Lead sponsor
Mount Carmel Health System
Other
Eligibility
65 Years and older · Female only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 5:36 PM EDT
Completed Phase 3 Interventional Results available

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

NCT00553410
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
4,884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 26, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

NCT05438303
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 26, 2026, 5:36 PM EDT
Not listed No phase listed Observational

Breast Cancer Tumor Heterogeneity

NCT02108561
View directory record Official record
Conditions
Breast Cancer
Interventions
Post Surgical Her2 testing
Other
Lead sponsor
Anne Arundel Health System Research Institute
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Annapolis, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 26, 2026, 5:36 PM EDT
Enrolling by invitation No phase listed Observational

Cardiotoxicity of Cancer Therapy (CCT)

NCT01173341
View directory record Official record
Conditions
Breast Cancer
Interventions
Echocardiography, Blood Collection, Symptoms Questionnaire
Diagnostic Test · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2037
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 26, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

NCT03199586
View directory record Official record
Conditions
Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Esophagus Cancer, Liver Cancer, Ovary Cancer, Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
NP-G2-044
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 26, 2026, 5:36 PM EDT
Active, not recruiting Not applicable Interventional

A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer

NCT06813053
View directory record Official record
Conditions
Breast Cancer
Interventions
Decision Aid (DA), Standard of Care (SOC)
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 26, 2026, 5:36 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2

NCT06082882
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
Education, Navigation to clinic
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 26, 2026, 5:36 PM EDT